Skip to main content

Asuragen Inks Distribution Deal for France

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Asuragen said today that Biomedical Diagnostics (BMD) will distribute its cancer assays in France.

The agreement covers Asuragen's Signature Oncology Portfolio, a line of multiplex assays used to detect mutations in solid and hematologic malignancies. The tests use RT-PCR and multiplex detection using the Luminex 100 or 200 systems.

The portfolio includes a research assay for KRAS and BRAF mutations, an IVD assay that uses RNA from blood or bone marrow to help diagnose certain leukemias, and an assay for simultaneous detection of common NPM1 mutations.

In addition, BMD will support Asuragen's efforts to establish clinical validation sites for the Signature KRAS/BRAF assay in France, Asuragen said.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.